2616 — CStone Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- HK$12.83bn
- HK$12.18bn
- CNY269.58m
Annual cashflow statement for CStone Pharmaceuticals, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | C2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -1,920 | -903 | -367 | -91.2 | -424 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 349 | 173 | -141 | -0.779 | 138 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 64.5 | 72.6 | -139 | -261 | -86 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -1,484 | -612 | -589 | -303 | -328 |
| Capital Expenditures | -149 | -102 | -65 | — | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -677 | 467 | 685 | -248 | 134 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Sale of Intangible Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -827 | 365 | 620 | -248 | 134 |
| Financing Cash Flow Items | -2.24 | -11.8 | -13.5 | -18.9 | -86.5 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 92.3 | 28.5 | 388 | -52.9 | 578 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -2,282 | -184 | 438 | -609 | 366 |